OA11351A - Use of antifungal agents for the topical treatmentof fungus-induced mucositis. - Google Patents

Use of antifungal agents for the topical treatmentof fungus-induced mucositis. Download PDF

Info

Publication number
OA11351A
OA11351A OA1200000119A OA1200000119A OA11351A OA 11351 A OA11351 A OA 11351A OA 1200000119 A OA1200000119 A OA 1200000119A OA 1200000119 A OA1200000119 A OA 1200000119A OA 11351 A OA11351 A OA 11351A
Authority
OA
OAPI
Prior art keywords
formulation
mammal
fungus
induced
antifungal
Prior art date
Application number
OA1200000119A
Other languages
English (en)
Inventor
Jens Ponikau
Original Assignee
Jens Ponikau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jens Ponikau filed Critical Jens Ponikau
Publication of OA11351A publication Critical patent/OA11351A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)

Claims (127)

  1. • 011351 - 73 - WHAT IS CLAIMED IS:
    1. A method for treating a mammal having non-invasive fungus-inducedrhinosinusitis, comprising mucoadministering to at least a portion of the nasal-paranasal anatomy of said mammal a formulation in an amount, at a frequency, and 5 for a duration effective to reduce or eliminate said non-invasive fungus-inducedrhinosinusitis, said formulation comprising an antifungal agent.
  2. 2. The method of claim 1, wherein said mammal is a human.
  3. 3. The method of claim 1, wherein said mammal is nonatopic.
  4. 4. The method of claim 1, wherein said mammal is immunocompétent.
  5. 5. The method of claim 1, wherein said non-invasive fungus-induced rhinosinusitis is characterized by polyp formation or polypoid change.
  6. 6. The method of claim 1, wherein said non-invasive fungus-induced rhinosinusitis is chronic.
    1. The method of claim 1, wherein said formulation is in a solid, liquid, or 15 aérosol form.
  7. 8. The method of claim 1, wherein said foAnulation is in a form selected from the group consisting of a powder, crystalline substance, gel, paste, ointment,salve, cream, solution, suspension, partial liquid, spray, nebulae, mist, atomizedvapor, aérosol, and tincture.
  8. 9. The method of claim 1, wherein said mucoadministration is a direct muco administration. 011351 - 74 -
  9. 10. The.method of daim 9, wherein said direct mucoadministrationcomprises irrigating said nasal-paranasal anatomy with a liquid form of saidformulation.
  10. 11. The method of claim 9, wherein said direct mucoadministration 5 comprises applying an aérosol form of said formulation to said nasal-paranasalanatomy.
  11. 12. The method of claim 9, wherein said direct mucoadministrationcomprises applying a powder form of said formulation to said nasal-paranasalanatomy.
  12. 13. The method of claim 1, wherein said antifungal agent comprises a macrolide.
  13. 14.. The method of claim 1, wherein said antifungal agent comprises anazole.
  14. 15. The method of claim 1, wherein said antifungal agent interpolâtes fungal 15 cell wall components.
  15. 16. The method of claim 1, wherein said antifungal agent comprises a sterolinhibitor. Y*. \
  16. 17. The method of claim 1, wherein said antifungal agent comprises anantifungal agent selected from the group consisting of amphotericin B, 20 kétoconazole, itraconazole, saperconazole, voriconazole, flucytosine, miconazole,fluconazole, eriseofulvin, clotrimazole, econazole, terconazole, butoconazole,oxiconazole, sulconazole, ciclopirox olamine, haloprogin, tolnaftate, naftifine, 011351 -75 · terbinafine hydr'ochloride, morpholines, nystatin, natamycin, butenafine,undecylenic acid, Whitefield’s ointmenî, propionic acid, and caprylic acid.
  17. 18. The method of claim 17, wherein said antifungal agent comprises anantifungal agent selected from the group consisting of amphotericin B, 5 kétoconazole, itraconazole, saperconazole, and voriconazole.
  18. 19. The method of claim 17, wherein said antifungal agent comprisesamphotericin B.
  19. 20. The method of claim 17, wherein said antifungal agent comprisesitraconazole.
  20. 21. The method of claim 1, wherein said formulation comprises a pharmaceutically acceptable aqueous vehicle.
  21. 22. The method of claim 21, wherein said formulation comprises about 0.01ng to about 1000 mg of said antifungal agent per liter.
  22. 23. The method of claim 22. wherein said effective amount comprises about15 0.01 mL to about 1 L of said formulation per nostril of said mammal. ' 24. The method of claim 22, wherein said_effective amount comprises about Ÿ‘ 5 mL to about 100 mL of said formulation per nostril of said mammal.
  23. 25. The method of claim 22, wherein said effective amount comprises about 20 mL of said formulation per nostril of said mammal.
  24. 26. The method of claim 21, wherein said formulation comprises about 1 ng to about 500 mg of said antifungal agent per liter. 011351 - 76 -
  25. 27. The-method of claim 21, wherein said formulation comprises about 100mg of said antifungal agent per liter.
  26. 28. The method of claim 1, wherein said formulation comprises a pluralityof antifungal agents.
  27. 29. The method of claim 1, wherein said effective amount of said formulation comprises about 0.01 ng to about 1000 mg of said antifungal agent perkg of body weight of said mammal.
  28. 30. The method of claim 1, wherein said effective amount of saidformulation comprises about 1 ng to about 500 mg of said antifungal agent per kg 10 of body weight of said mammal.
  29. 31. The method of claim 1, wherein said effective amount of saidformulation remains constant during said effective duration.
  30. 32. The method of claim 1, wherein said effective frequency of saidmucoadministration is from about four times a day to about once every other week.
  31. 33. The method of claim 1, wherein said effective frequency of said mucoadministration is from about twice a day to about once a week.
  32. 34. The method of claim 1, wherein said effective frequency of saidmucoadministration is more frequent than once a day.
  33. 35. The method of claim 1, wherein said effective frequency of said 20 mucoadministration is more frequent than once a week. 011351 - 77 -
  34. 36. Themèthod of claim 1, wherein said effective duration is greater thanabout 7 daÿs.
  35. 37. The method of claim 1, wherein said effective duration is greater thanabout 14 days.
  36. 38. The method of claim 1, wherein said effective duration is greater thanabout 30 days.
  37. 39. The method of claim 1, wherein said effective duration is greater thanabout 60 days.
  38. 40. The method of claim 1, wherein said effective duration is greater than 10 about 90 days. 41. ·. The method of claim 1, wherein said formulation comprises a compound selected front the group consisting of pharmaceutically acceptable aqueous vehicles,pharmaceutically acceptable solid vehicles, mucolytic agents, antibacterial agents,anti-inflammatory agents, immunosuppressants, dilators, vaso-constrictors, steroids, 15 and therapeutic compounds.
  39. 42. The method of claim 1, wherein said method comprises administering to - said mammal a second formulation. x__ y·
  40. 43. The method of claim 42, wherein said second formulation comprises acompound selected from the group consisting of antifungal agents, pharmaceutically 20 acceptable aqueous vehicles, pharmaceutically acceptable solid vehicles, mucolytic agents, antibacterial agents, anti-inflammatory agents, immunosuppressants, dilators, vaso-constrictors, steroids, and therapeutic compounds. - 78 - 011Ξ51
  41. 44. The method of claim 1, said method comprising, after saidmucoadministration, prophylactically mucoadministering to said mammal aprophylactic formulation in an amount, at a frequency, and for a duration effectiveto prevent said non-invasive fungus-induced rhinosinusitis, said prophylactic 5 formulation comprising an antifungal agent.
  42. 45. The method of claim 44, wherein said prophylactic mucoadministrationcomprises direct mucoadministration.
  43. 46. A method for prophylactically treating a mammal at risk for developingnon-invasive fungus-induced rhinosinusitis, comprising mucoadministering to said 10 mammal a formulation in an amount, at a frequency, and for a duration effective toprevent said non-invasive fungus-induced rhinosinusitis, said formulationcomprising an antifungal agent.
  44. 47. A method for treating a mammal having a non-invasive fungus-inducedrhinosinusitis, comprising the steps of: 15 a) identifying said mammal, and b) directly mucoadministering to at least a portion of the nasal-paranasalanatomy of said mammal a formulation in an amount, at a frequency, and for aduration effective to reduce or eliminate said non-invasive fungus-inducedrhinosinusitis, said formulation comprising an antifungal agent. 2Q 48. The method of claim 47, wherein said identifying comprises diagnosing. λ '
  45. 49. A method for prophylactically treating a mammal at risk for developing non-invasive fungus-induced rhinosinusitis, comprising the steps of: a) identifying said mammal, and b) mucoadministering to at least a portion of the nasal-paranasal 25 anatomy of said mammal a formulation in an amount, at a frequency, and for a 011351 - 79 - duration effective’to prevent said non-invasive fungus-induced rhinosinusitis, saidformulation comprising an antifungal agent.
  46. 50. A method for treating a mammal having astnma, comprisingmucoadministering to at least a portion of the airways of said mammal a 5 formulation in an amount, at a frequency, and for a duration effective to reduce oreliminate symptoms of said asthma, said formulation comprising an antifungalagent..
  47. 51. The method of claim 50, wherein said mucoadministration comprises adirect mucoadministration.
  48. 52. The method of claim 51, wherein said direct mucoadministration comprises imgating the nasal-paranasal anatomy of said mammal with a liquidform of said formulation.
  49. 53. The method of claim 51, wherein said direct mucoadministration comprises inhaling said formulation through the mouth or nose of said mammal.
  50. 54. The method of claim 50, wherein said portion comprises nasal airways.
  51. 55. The method of claim 50, wherein said portion comprises lung airways.
  52. 56. The method of claim 50, said method comprising, after saidmucoadministration, prophylactically mucoadministering to said mammal aprophylactic formulation in an amount, at a frequency, and for a duration effective 20 to prevent symptoms of said asthma, said prophylactic formulation comprising an antifungal agent. - 80 -
  53. 57. A method for prophylactically treating a mammal at risk for developing asthma, comprising mucoadministering to at least a portion of the airways of saidmammal a formulation in an amount, at a frequency, and for a duration effective toprevent symptoms of said asthma, said formulation comprising an antifungal agent. 5 58. A method for treating a mammal having asthma, comprising the steps of: a) identifying said mammal, and b) directly mucoadministering to at least a portion of the airways of saidmammal a formulation in an amount, at a frequency, and for a duration effective to 10 reduce or eliminate symptoms of said asthma, said formulation comprising anantifungal agent.
  54. 59. A method for prophylactically treating a mammal at risk for developingasthma, comprising the steps of: a) identifying said mammal, and 15 b) mucoadministering to at least a portion of the airways of said mammal a formulation in an amount, at a frequency, and for a duration effective toprevent symptoms of said asthma, said formulation comprising an antifungal agent.
  55. 60. A method for treating a mammal having non-invasive fungus-inducedintestinal mucositis, comprising mucoadministering to said mammal a formulation 20 in an amount, at a frequency, and for a duration effective to reduce or eliminate- said non-invasive fungus-induced intestinal mucositis, said formulation comprising an antifungal agent.
  56. 61. A method for prophylactically treating a mammal at risk for developingnon-invasive fungus-induced intestinal mucositis, comprising mucoadministering to 25 said mammal a formulation in an amount, at a frequency, and for a duration . 011351 - 81 - effective to prevent said non-invasive fungus-induced intestinal mucositis, saidformulation comprising an antifungal agent.
  57. 62. À method for treating a mammal having a non-invasive fungus-induced intestinal mucositis, comprising the steps of: 5 a) identiîying said mammal, and b) mucoadministering to at least a portion of the digestive tract of saidmammal a formulation in an amount, at a frequency, and for a duration effective toreduce or eliminate said non-invasive fungus-induced intestinal mucositis, saidformulation comprising an antifungal agent.
  58. 63. The method of claim 62, wherein said identifying comprises diagnosing.
  59. 64. A method for prophylactically treating a mammal at risk for developingnon-invasive fungus-induced intestinal mucositis, comprising the steps of: a) identifying said mammal, and b) mucoadministering to at least a portion of the digestive tract of said 15 mammal a formulation in an amount, at a frequency, and for a duration effective toprevent said non-invasive fungus-induced intestinal mucositis, said formulationcomprising an antifungal agent.
  60. 65. A method for treating a mammal having non-invasive fungus-induced- otitis media, comprising mucoadministering to -said mammal a formulation in an Z , 20 amount, at a frequency, and for a duration effective"to reduce or eliminate said s non-invasive fungus-induced otitis media, said formulation comprising an antifungalagent.
  61. 66. A method for prophylactically treating a mammal at risk for developingnon-invasive fungus-induced otitis media, comprising mucoadministering to'said 25 mammal a formulation in an amount, at a frequency, and for a duration effective to 011 Γ < - 82 - prevent said non-invasive funsus-induced otitis media, said formulation comorisin^an antifungal agent.
  62. 67. A method for treating a mammal having a non-invasive fungus-induced otitis media, comprising the steps of: 5 a) identifying said mammal, and b) mucoadministering to at least a portion of the middle ear of said mammal a formulation in an amount, at a frequency, and for a duration effective toreduce or eliminate said non-invasive fungus-induced otitis media, said formulationcomprising an antifungal agent.
  63. 68. The method of ciaim 67, wherein said identifying comprises diagnosins.
  64. 69. A method for prophylactically treating a mammal at risk for developing non-invasive fungus-induced otitis media, comprising the steps of: a) identifying said mammal, and b) mucoadministering to at least a portion of the middle ear of said 15 mammal a formulation in an amount, at a frequency, and for a duration effective toprevent said non-invasive fungus-induced otitis media, said formulation comprisingan antifungal agent.
  65. 70. An article of manufacture, comprising packaging material and a formulation contained within said packaging material, wherein said formulationcomprises an antifungal agent and wherein said packaging material comorises a label or package insert indicating that said formulation can ce directiy mucoadministered to at least a portion of the nasal-paranasai anatomv of a mammal having non-invasive fungus-induced rhinosinusitis in an amount, at a ffequencv,and for a duration effective to reduce cr eliminate said non-invasive furisus-induced 25 rhinosinusitis. 011351 - 83 -
  66. 71. An article of manufacture, comprising packaging material and aformulation contained within said packaging material, wherein said formulationcomprises an antifungal agent and wherein said packaging material comprises alabel or package insert indicating that said formulation can be mucoadministered to 5 at least a portion of the nasal-paranasal anatomy of a mammal at risk fordeveloping non-invasive fungus-induced rhinosinusitis in an amount, at afrequency, and for a duration effective to prevent said non-invasive fungus-inducedrhinosinusitis.
  67. 72. An article of manufacture, comprising packaging material and a 10 formulation contained within said packaging material, wherein said formulationcomprises an antifungal agent and wherein said packaging material comprises alabel or package insert indicating that said formulation can be directlymucoadministered to at least a portion of the airways of a mammal having asthmain an amount, at a frequency, and for a duration effective to reduce or eliminate 15 symptoms of said asthma.
  68. 73. An article of manufacture, comprising packaging material and aformulation contained within said packaging material, wherein said formulationcomprises an antifungal agent and wherein said packaging material comprises alabel or package insert indicating that said formulation can be mucoadministered to 20 at least a portion of the airways of a mammal at risk for developing asthma in anamount, at a frequency, and for a duration effective to prevent symptoms of saidasthma. >''
  69. 74. An article of manufacture, comprising packaging material and aformulation contained within said packaging material, wherein said formulation 25 comprises an antifungal agent and wherein said packaging material comprises alabel or package insert indicating that said formulation can be mucoadministered toa mammal having non-invasive fungus-induced intestinal mucositis in an amount, at - 84 - a frequency, and for a duration effective to reduce or eiiminate said non-invasivefungus-induced intestinal mucositis.
  70. 75. An article of manufacture, comprising packaging material and a formulation contained within said packaging material, wherein said formulation5 comprises an antifungal agent and wherein said packaging material comprises alabel or package insert indicating thaï said formulation can be mucoadministered toa mammal at risk for developing non-invasive fungus-induced intestinal mucositisin an amount, at a frequency, and for a duration effective to prevent said non-invasive fungus-induced intestinal mucositis.
  71. 76. An article of manufacture, comprising packaging material and a formulation contained within said packaging material, wherein said formulationcomprises an antifungal agent and wherein said packaging material comprises alabel or package insert indicating that said formulation can be mucoadministered toa mammal having non-invasive fungus-induced otitis media in an amount, at a 15 frequency, and for a duration effective to reduce or eiiminate said non-invasivefungus-induced otitis media.
  72. 77. An article of manufacture, comprising packaging material and a formulation contained within said packaging material, wherein said formulationcomprises an antifungal agent and wherein said packaging material comprises a 20 label or package insert indicating that said formulation can be mucoadministered toa mammal ai risk for deveicping non-invasive fungps-induced otitis media in anamount. at a freouencv. and for a duration effective to nrevent said non-invasive fungus-induced otitis media.
  73. 78. The use of an antifungal agent in the manufacture of a médicament for 25 treating or preventing non-invasive fungus-induced rhinosinusitis. 011351 - 85 -
  74. 79. The "use as in claim 78, wherein said médicament is mucoadministered to at least a portion of the nasal-paranasal anatomy of a mammal in an amount, at a frequency, and for a duration effective to reduce, eliminate, or prevent said non- invasive fungus-induced rhinosinusitis.
  75. 80. The use as in claim 79, wherein said mucoadministration is a directmucoadministration.
  76. 81. The use as in claim 80, wherein said direct mucoadministrationcomprises irrigating said nasal-paranasal anatomy with a liquid form of saidmédicament.
  77. 82. The use as in claim 80, wherein said direct mucoadministrationcomprises applying an aérosol form of said médicament to said nasal-paranasalanatomy.
  78. 83. The use as in claim 80, wherein said direct mucoadministrationcomprises applying an powder form of said médicament to said nasal-paranasal 15 anatomy.
  79. 84. The use as in claim 79, wherein said effective amount comprises about0.01 mL to about 1 L of said médicament per nostril of said mammal.
  80. 85. The use as in claim 79, wherein said effective amount of saidmédicament remains constant during said effective duration.
  81. 86. The use as in claim 79, wherein said effective frequency of sâid mucoadministration is from about four times a day to about once every other week. 011351 - 86 -
  82. 87. The.use as in claim 79, wherein said effective duration is greater thanabout 7 days.
  83. 88. The use as in claim 78, wherein said non-invasive fungus-inducedrhinosinusitis is characterized by polyp formation or polypoid change.
  84. 89. The use as in claim 78, wherein said non-invasive fungus-induced rhinosinusitis is chronic.
  85. 90. The use as in claim 78, wherein said médicament is in a solid, liquid, oraérosol form.
  86. 91. The use as in claim 78, wherein said médicament is in a form selected10 from the group consisting of a powder, crystalline substance, gel, paste, ointment, salve, créant, solution, suspension, partial liquid, spray, nebulae, mist, atomizedvapor, aérosol, and tincture.
  87. 92. The use as in claim 78, wherein said antifungal agent comprises amacrolide.
  88. 93. The use as in claim 78, wherein said antifungal agent comprises an azole.
  89. 94. The use as in claim 78, wherein said antifungal agent comprises an antifungal agent selected front the group consisting of amphotericin B,kétoconazole, itraconazole, saperconazole, voriconazole, flucytosine, miconazole, 20 fluconazole, griseofulvin, clotrimazole, econazole, terconazole, butoconazole,oxiconazole, sulconazole, ciclopirox olamine, haloprogin, tolnaftate, naftifine,terbinafme hydrochloride, morpholines, nystatin, natamycin, butenafine,undecylenic acid, Whitefield’s ointment, propionic acid, and caprylic acid. 01 1 - 87 -
  90. 95. Theuse as in claim 78, wherein said médicament comprises apharmaceutically acceptable aqueous vehicle.
  91. 96. The use as in claim 95, wherein said médicament comprises about 1 ngto about 500 mg of said antifungal agent per liter.
  92. 97. The use as in claim 95, wherein said médicament comprises about 100mg of said antifungal agent per . liter.
  93. 98. The use as in claim 78, wherein said médicament comprises about 0.01ng to about 1000 mg of said antifungal agent per liter.
  94. 99. The use as in claim 78, wherein said médicament comprises a plurality10 of antifungal agents.
  95. 100. The use as in claim 78, wherein said médicament comprises a compoundselected ffom the group consisting of pharmaceutically acceptable aqueous vehicles,pharmaceutically acceptable solid vehicles, mucolytic agents, antibacterial agents,anti-inflammatory agents, immunosuppressants, dilators, vaso-constrictors, steroids, 15 and therapeutic compounds.
  96. 101. . The use of an antifungal agent in the manufacture of a médicament for treating or preventing asthma. __ v
  97. 102. The use as in claim 101, wherein said médicament is mucoadministeredto at least a portion of the airways of a mammal in an amount, at a frequency, and 20 for a duration effective to reduce, eliminate, or prevent symptoms of said asthma.
  98. 103. The use of an antifungal agent in the manufacture of amedicament fortreating or preventing non-invasive fungus-induced intestinal mucositis. 011Z51 - 88 -
  99. 104. The.use as in claim 103, wherein said médicament is mucoadministeredto a mammal in an amount, at a frequency, and for a duration effective to reduce,eliminate, or prevent symptoms of said non-invasive fungus-induced intestinalmucositis.
  100. 105. The use of an antifungal agent in the manufacture of a médicament fortreating or preventing non-invasive fungus-induced otitis media.
  101. 106. The use as in claim 105, wherein said médicament is mucoadministeredto a mammal in an amount, at a frequency, and for a duration effective to reduce,eliminate, or prevent symptoms of said non-invasive fungus-induced otitis media.
  102. 107. An antifungal formulation comprising an antifungal agent, a flavoring,and water, wherein said water comprises at least about 50 percent of saidformulation.
  103. 108. The antifungal formulation of claim 107, wherein said water comprisesat least about 75 percent of said formulation.
  104. 109. The antifungal formulation of claim 107, wherein said water comprisesat least about 85 percent of said formulation.
  105. 110. An antifungal formulation comprising an antifungal agent, a flavoring,and water, wherein said water comprises at least abcut 50 percent of saidformulation, and wherein said antifungal agent comprises an antifungal agent20 selected from the group consisting of amphotericin B, kétoconazole, saperconazoie,voriconazole, flucytosine, miconazole. fiuconazole, griseofulvin, clotrimazole,econazole, terconazoie, butoconazole, oxiconazole, sulconazole, ciclopirox oinmlne.halccrozin. tclnafznte. nafriflns. terhinaflze hvcrcchlcride. mcmhcüne" rv^tatin 011351 - 89 - natamycin, butenafine, undecylenic acid, Whitefield’s ointment, propionic acid, andcaprylic acid.
  106. 111. An antifungal formulation comprising itraconazole and water, whereinsaid itraconazole is dissolved in said formulation at a concentration greater than 5 about 25 pg per mL and wherein said water comprises at least about 50 percent ofsaid formulation.
  107. 112. The antifungal formulation of ciaim 111, wherein said formulationcomprises polyethylene glycol.
  108. 113. The antifungal formulation of ciaim 111, wherein said formulation 10 comprises a flavoring.
  109. 114. An antifungal formulation comprising itraconazole and water, whereinsaid itraconazole is suspended in said formulation at a concentration greater thanabout 25 pg per mL and wherein said water comprises at least about 50 percent ofsaid formulation. 15 115. A method of making an antifungal formulation, said formulation comprising itraconazole and water, wherein said itraconazole is dissolved in saidformulation at a concentration greater than about 25 pg per mL and wherein saidwater comprises at least about 50 percent of said. formulation, said methodcomprising adding said water to a stock solution coritaining said itraconazole. 20 116. A method for culturing fungus from a mammaFs mucus, said methodcomprising: a) contactas said mucus with a mucolvtic agent to reduce the viscosityof said mucus, b) separating said fungus from said reduced-viscosity mucus, - 90- c) contacting said separated fungus with fungus growth medium to forma fungus culture, and d) incubating said fungus culture such that said separated fungus grows.
  110. 117. A method for obtaining a fungal antigen, said method comprising: 5 a) contacting a mammal’s mucus with a mucolytic agent to reduce the viscosity of said mucus, b) separating fungus from said reduced-viscosity mucus, c) contacting said separated fungus with fungus growth medium to forma fungus culture, 10 d) incubating said fungus culture such that said separated fungus grows, and e) isolating said antigen from said cultured fungus.
  111. 118. A method for producing a fungus-specific antibody, said methodcomprising: 15 a) contacting a mammal’s mucus with a mucolytic agent to reduce the viscosity of said mucus, b) separating fungus from said reduced-viscosity mucus, c) contacting said separated fungus with fungus growth medium to forma fungus culture, 20 d) incubating said fungus culture such that said separated fungus grows, e) isolating a fungal antigen from said cultured fungus, and f) immunizing an animal with said fungal'. antigen to produce said antibody.
  112. 119. A nasal mucus collecting apparatus, comprising:a) a collection retainer, said collection retainer being suitable for retaining mucus, 25 011351 - 91 - b) a'eollection tube extending from said collection retainer, wherein saidcollection tube defines a distal end and a;- lumen such that mucus can traverse saidlumen from said distal end of said collection tube to said collection retainer, saidcollection tube being generally flexible over at least a portion of the length of said5 collection tube such that said collection tube can be selectively manipulated into adesired configuration by a practitioner during a collection procedure, said collectiontube furiher being generally malléable such that said collection tube generallyretains said desired configuration until the practitioner manipulâtes said collectiontube to conform to a different configuration, and 10 c) a connecting portion extending from said collection retainer, wherein said connecting portion defines a second lumen that communicates with the interiorof said collection retainer, said connecting portion being adapted to receive avacuum source.
  113. 120. The apparatus of claim 119, wherein said apparatus comprises a valve 15 that adjusts the opening of said second lumen.
  114. 121. The apparatus of claim 119, wherein said collection retainer isremovable from said collection tube and said connection portion.
  115. 122. A pharmaceutical composition comprising an antifungal agent ·' 123. A pharmaceutical composition comprising an antifungal agent and a V*·' 20 mucolytic agent
  116. 124. A pharmaceutical composition comprising an antifungal agent and asteroid.
  117. 125. A pharmaceutical composition comprising an antifungal agent and adecongestant. 01135 ι - 92 -
  118. 126. A pharmaceutical composition comprising an antifungal agent and anantibiotic.
  119. 127. A pharmaceutical composition comprising an antifungal agent and ananti-inflammatory. 5 128. A composition for treating an immune response to fungus in a mammal, characterized by an agent configured for direct mucoadministration to the mucus ofthe mammal and having antifungal means for eliminating or reducing the fungusbelow a threshold level wherein the fungus ceases to activate éosinophile migrationto the affected area. 10 129. A pharmaceutical composition for treating a fungal related condition in the nasal-sinus anatomy, pulmonary anatomy, ear anatomy, or intestinal anatomy ofa mammalian patient, said composition comprising an effective dose of an anti-fungal as described herein.
  120. 130. A pharmaceutical composition for treating a fungal related condition in 15 the nasal-sinus anatomy, pulmonary anatomy, ear anatomy, or intestinal anatomy ofa mammalian patient, said composition comprising an effective dose of an anti-fungal and at least one other agent or inhibitor as described herein.
  121. 131. A pharmaceutical composition for treating a fungal related condition inthe nasal sinus anatomv, pulmonarv anatomv, ear anatomy, or intestinal anatomv of λ ' 20 a mammalian patient, said composition comprising an effective dose of an anti-fungal suitable for long term use within the nasal-sinus anatomy.
  122. 132. A médication for treating sinusitis, asthma, otitis media, or colitis of apatient, comprising a mucolytic agent; and an anti-fungal compound as describedherein. 011351 - 93 -
  123. 133. An-irrigation médication for treating an inflamed nasal area, lung area,ear area, or intestinal area of a patient, the inflamed nasal area, lung area, ear area,or intestinal area being caused by the presence of a fungus, the médicationcomprising effective doses of an antifungal compound and a steroid as described 5 herein.
  124. 134. An irrigation médication for treating an inflamed nasal area, lung area,ear area, or intestinal area of a. patient, the inflamed nasal area, lung area, ear area,or intestinal area being causedby the presence of a fungus, the médicationcomprising effective doses of an antifungal compound and a mucolytic agent.
  125. 135. An irrigation médication for treating an inflamed nasal area, lung area, ear area, or intestinal area of a patient, the inflamed nasal area, lung area, ear area,or intestinal area being caused by the presence of a fungus, the médicationcomprising effective doses of a steroid and a mucolytic agent as described herein.
  126. 136. .An irrigation médication for treating an inflamed nasal area, lung area. 15 ear area, or intestinal area of a patient, the inflamed nasal area, lung area, ear area, or intestinal area being caused by the presence of a fungus, the médicationcomprising effective doses of an antifungal compound, a steroid, and a mucolyticagent as described herein.
  127. 137. - An irrigation médication for treating_an inflamed nasal area, lung area, 20 ear area, or intestinal area of a patient, the inflame^· -nasal area, lung area, ear area. or intestinal area being caused by the presence of a fungus. the médicationcomprising .an effective dose of ai least one medicine selected èom the groupconsisting of an antifungal compound, a steroid, a mucciytic agent, and anycombination thereof as described herein.
OA1200000119A 1997-10-22 2000-04-20 Use of antifungal agents for the topical treatmentof fungus-induced mucositis. OA11351A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6270997P 1997-10-22 1997-10-22
US6341497P 1997-10-28 1997-10-28
US6341897P 1997-10-28 1997-10-28
US8327298P 1998-04-28 1998-04-28
US8639798P 1998-05-22 1998-05-22

Publications (1)

Publication Number Publication Date
OA11351A true OA11351A (en) 2003-12-18

Family

ID=27535591

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000119A OA11351A (en) 1997-10-22 2000-04-20 Use of antifungal agents for the topical treatmentof fungus-induced mucositis.

Country Status (27)

Country Link
US (9) US20020052390A1 (fr)
EP (2) EP1857113A3 (fr)
JP (3) JP2001520188A (fr)
KR (4) KR20070069220A (fr)
CN (1) CN1143679C (fr)
AP (1) AP2000001805A0 (fr)
AT (1) ATE371457T1 (fr)
AU (1) AU1195999A (fr)
BG (1) BG104371A (fr)
BR (1) BR9814615A (fr)
CA (1) CA2308201C (fr)
DE (1) DE69838338T2 (fr)
DK (1) DK1024814T3 (fr)
EA (1) EA200000439A1 (fr)
EE (1) EE200000253A (fr)
ES (1) ES2292210T3 (fr)
HU (1) HUP0004170A3 (fr)
ID (1) ID26104A (fr)
IL (2) IL135774A0 (fr)
IS (1) IS5463A (fr)
NO (1) NO325714B1 (fr)
OA (1) OA11351A (fr)
PL (1) PL340606A1 (fr)
PT (1) PT1024814E (fr)
SK (1) SK5732000A3 (fr)
TR (1) TR200001117T2 (fr)
WO (1) WO1999020261A2 (fr)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045815A (en) * 1997-08-15 2000-04-04 Board Of Regents, The University Of Texas System Parenteral pimaricin as treatment of systemic infections
US6844004B2 (en) 1997-08-15 2005-01-18 Board Of Regents, The University Of Texas System Topical formulations of natamycin/pimaricin
US20020052390A1 (en) * 1997-10-22 2002-05-02 Jens Ponikau Methods and materials for treating and preventing inflammation of mucosal tissue
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
AU5975700A (en) * 1999-07-02 2001-01-22 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
SE521431C2 (sv) * 1999-12-02 2003-11-04 Sca Hygiene Prod Ab Användning av en pH-buffrande substans för att förhindra hudinfektioner orsakade av Candida Albicans
US6930125B2 (en) * 2000-01-14 2005-08-16 John F. Hunt Airway alkalinization as a therapy for airway diseases
WO2001060395A2 (fr) * 2000-02-18 2001-08-23 Eli Lilly And Company Procedes servant a traiter une inflammation de la muqueuse non invasive provoquee par un champignon au moyen d'agents antifongiques de cyclohexapeptides
US7048953B2 (en) * 2000-04-03 2006-05-23 Inhalation, Inc. Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS)
US7150888B1 (en) 2000-04-03 2006-12-19 Inhalation, Inc. Methods and apparatus to prevent colds, influenzaes, tuberculosis and opportunistic infections of the human respiratory system
US7473433B2 (en) 2000-12-21 2009-01-06 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US6767537B2 (en) 2000-05-26 2004-07-27 Phil Arnold Nicolay Composition and method for the treatment of sinusitis
WO2002007682A1 (fr) * 2000-07-26 2002-01-31 Vyden John K Procedes de traitement de troubles atopiques
WO2002022118A1 (fr) * 2000-09-14 2002-03-21 Waldemar Gottardi Produit fongicide contenant de la n-chlorotaurine et son utilisation
US6685917B2 (en) * 2000-11-22 2004-02-03 Rxkinetix, Inc. Treatment of mucositis
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
US7770577B2 (en) * 2001-05-15 2010-08-10 Gregory E Conner Methods and devices for treating lung dysfunction
WO2002098463A1 (fr) * 2001-06-05 2002-12-12 The New Industry Research Organization Compositions antifongiques
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
US20040019316A1 (en) * 2002-03-13 2004-01-29 Morris John K. Nasal airway delivery, decongestion system (NADDS)
RU2227000C2 (ru) * 2002-05-24 2004-04-20 ГУ Научно-клинический центр оториноларингологии Способ лечения хронических гнойных мезотимпанитов
AU2003259028A1 (en) * 2002-06-10 2003-12-22 Combinatorx, Incorporated Combinations for the treatment of rheumatoid arthritis
WO2004000272A1 (fr) * 2002-06-20 2003-12-31 Novartis Consumer Health S.A. Compositions nasales contenant un glycosaminoglycane et un propylene glycol
US20050032896A1 (en) * 2002-06-21 2005-02-10 Liisa Neumann Use of synthetic retinoic acid in form of 13-cis vitamin A for treatment of autism
AU2003244633A1 (en) * 2002-07-02 2004-01-23 Novartis Ag Methods for the treatment of sinusitis
US20040029893A1 (en) * 2002-07-23 2004-02-12 Lane Edward M. Method of treatment of non-invasive mucositis
ES2428354T3 (es) 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
KR101301653B1 (ko) * 2002-10-29 2013-08-30 트랜세이브, 인코포레이티드 항감염제의 지속적인 방출
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
AU2003304239A1 (en) * 2002-11-13 2005-01-13 Yvonne J. Rosenberg A pretreatment or post exposure treatment for exposure to a toxic substance by pulmonary delivery (inhaler) of a bioscavenger
US6890323B1 (en) * 2002-12-03 2005-05-10 University Of Florida Small volume effusion trap
EP1581182A2 (fr) * 2002-12-31 2005-10-05 Nektar Therapeutics Formulation pharmaceutique administree en aerosol dans une therapie destinee a traiter une infection fongique
CA2518960C (fr) * 2003-03-14 2013-08-27 Sinexus, Inc. Administration dans un sinus d'agents therapeutiques a liberation prolongee
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US20070078116A1 (en) * 2003-08-20 2007-04-05 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20050043251A1 (en) * 2003-08-20 2005-02-24 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20050159369A1 (en) * 2003-08-20 2005-07-21 Qtm Llc Method of treatment of otitis externa
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20060177424A1 (en) * 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US7731976B2 (en) * 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US7749509B2 (en) * 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
CN100534334C (zh) * 2003-09-09 2009-09-02 3M创新有限公司 浓缩的抗菌组合物和方法
BRPI0414193A (pt) * 2003-09-09 2006-10-31 3M Innovative Properties Co composição antimicrobiana, kit antimicrobiano e métodos de usar a composição e de aplicar uma composição antimicrobiana a um substrato
US9072728B2 (en) * 2003-09-18 2015-07-07 Children's Medical Center Corporation Treatment of severe distal colitis
JP2007505932A (ja) 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
KR100978717B1 (ko) 2003-12-08 2010-08-30 씨펙스 파마슈티칼스, 인코포레이티드 인슐린 치료를 위한 약제 조성물 및 방법
US20070196457A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US20070196325A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for dermally treating infections
US8907153B2 (en) 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US20070196293A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for treating photo damaged skin
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US20070190124A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs
US20070196453A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
US20080019927A1 (en) * 2004-06-07 2008-01-24 Jie Zhang Compositions and methods for dermally treating neuropathy with minoxidil
US8741333B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US20070189978A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Compositions and methods for dermally treating musculoskeletal pain
US20060009424A1 (en) * 2004-07-06 2006-01-12 Anatoly Kogan Nasaleaze
PL1776109T3 (pl) * 2004-08-13 2009-06-30 Schering Plough Ltd Farmaceutyczna formulacja zawierająca antybiotyk, triazol i kortykosteroid
US8198326B2 (en) * 2004-09-07 2012-06-12 3M Innovative Properties Company Phenolic antiseptic compositions and methods of use
US9028852B2 (en) 2004-09-07 2015-05-12 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use
US8109981B2 (en) * 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
KR100675379B1 (ko) * 2005-01-25 2007-01-29 삼성전자주식회사 프린팅 시스템 및 프린팅 방법
WO2006086750A1 (fr) 2005-02-09 2006-08-17 Macusight, Inc. Formulations liquides pour le traitement de maladies ou affections
JP2008533048A (ja) * 2005-03-10 2008-08-21 スリーエム イノベイティブ プロパティズ カンパニー 耳の感染症の治療方法
KR20070113281A (ko) * 2005-03-10 2007-11-28 쓰리엠 이노베이티브 프로퍼티즈 컴파니 항미생물성 조성물 및 방법
EP2497460A1 (fr) * 2005-03-10 2012-09-12 3M Innovative Properties Co. Procédés de réduction de contamination microbienne
US20060229364A1 (en) * 2005-03-10 2006-10-12 3M Innovative Properties Company Antiviral compositions and methods of use
US20060204558A1 (en) * 2005-03-10 2006-09-14 Kantner Steven S Antimicrobial pet wipes and methods
EP2298318A1 (fr) 2005-04-04 2011-03-23 Sinexus, Inc. Dispositifs et procédés de traitement des affections sinus paranasaux
US7670849B2 (en) * 2005-04-29 2010-03-02 Henkin Robert I Method for diagnosing insulin resistance from nasal secretions
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US8246946B2 (en) * 2005-09-27 2012-08-21 Cobb & Associates Treatment of bipolar disorder utilizing anti-fungal compositions
ITRM20050561A1 (it) * 2005-11-10 2007-05-11 D M G Italia S R L Soluzione otologica e metodo per la sua preparazione.
DK1965787T3 (da) * 2005-11-30 2013-06-03 Endo Pharmaceuticals Inc Behandling af xerostomi med en svovlindeholdende antioxidant
JP5324223B2 (ja) 2005-12-08 2013-10-23 トランセイブ， インク． 肺感染症を治療する抗感染薬の脂質ベースの組成物及びその使用法
WO2007070661A2 (fr) * 2005-12-13 2007-06-21 Naryx Pharma, Inc. Méthodes pour mesurer des symptômes de rhinosinusite chronique
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US20070219600A1 (en) * 2006-03-17 2007-09-20 Michael Gertner Devices and methods for targeted nasal phototherapy
CN101443004B (zh) 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
US20100190735A1 (en) * 2006-03-28 2010-07-29 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
WO2007117550A2 (fr) * 2006-04-06 2007-10-18 Transave, Inc. Procédés d'encapsulation liposomale induite par coacervation et formulations associées
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
US20070286813A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
US20070286812A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
US8535707B2 (en) 2006-07-10 2013-09-17 Intersect Ent, Inc. Devices and methods for delivering active agents to the osteomeatal complex
US20080131420A1 (en) * 2006-07-13 2008-06-05 Accentia, Inc. Methods and compositions for treating mucosal inflammation
US20080075793A1 (en) * 2006-09-21 2008-03-27 Dunshee Wayne K Antiviral compositions and methods of use
WO2008039987A2 (fr) * 2006-09-28 2008-04-03 Transave, Inc. Méthodes destinées à traiter la détresse pulmonaire
WO2008063756A2 (fr) * 2006-10-03 2008-05-29 Accentia Biopharmaceuticals, Inc. Formulation d'amphotéricine b n'irritant pas les muqueuses, et procédés pour traiter une mucosite non-invasive induite par un champignon
AU2007317622B2 (en) 2006-10-27 2010-12-16 3M Innovative Properties Company Antimicrobial compositions
US20110146671A1 (en) * 2006-12-01 2011-06-23 James Zhou Liu Pharmaceutical compositions and methods of delivering the same
WO2008095136A2 (fr) 2007-01-31 2008-08-07 Henkin Robert I Procédés de détection de substances biologiques
JP2010526087A (ja) * 2007-04-30 2010-07-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗ｉｌ−５抗体を投与するための方法
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US20090198179A1 (en) 2007-12-18 2009-08-06 Abbate Anthony J Delivery devices and methods
CN101214221A (zh) * 2007-12-27 2008-07-09 黄明 治疗鼻炎鼻窦炎药物制剂
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
JP5917143B2 (ja) * 2008-03-28 2016-05-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 処置方法
WO2009146104A1 (fr) * 2008-04-02 2009-12-03 Accentia Biopharmaceuticals, Inc. Formulations, dispositifs et procédés pour traiter et prévenir une mucosite
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
BRPI0910850B1 (pt) 2008-04-21 2022-06-14 Otonomy, Inc. Composição intratimpânica compreendendo fator neurotrófico de crescimento derivado do cérebro (bdnf) para o tratamento ou prevenção da perda auditiva
WO2009139924A2 (fr) 2008-05-14 2009-11-19 Otonomy, Inc. Compositions de corticostéroïdes à libération contrôlée et procédés pour le traitement de troubles otiques
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
BRPI0916323A2 (pt) * 2008-07-21 2018-05-29 Otonomy Inc composições antimicrobianas de liberação controlada e métodos para o tratamento de distúrbios do ouvido
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
AU2009276505B2 (en) 2008-08-01 2015-04-23 Intersect Ent, Inc. Methods and devices for crimping self-expanding devices
CA2761769C (fr) 2009-05-15 2018-06-05 Intersect Ent, Inc. Dispositifs expansibles et procedes pour les utiliser
WO2011100170A1 (fr) * 2010-02-10 2011-08-18 Albert Cha Systèmes d'irrigation nasale
GB2481712B (en) * 2010-06-30 2013-01-30 Pangaea Lab Ltd Composition comprising vascular endothelial growth factor (VEGF) for the treatment of hair loss
US9669044B2 (en) 2010-12-14 2017-06-06 Utah State University Aminoglycoside and azole compositions and methods
CN104105472A (zh) 2011-12-20 2014-10-15 维奥姆生物科学有限公司 用于治疗真菌感染的局部油组合物
PL2852391T3 (pl) 2012-05-21 2022-04-11 Insmed Incorporated Układy do leczenia infekcji płuc
MX2015006681A (es) 2012-11-29 2016-04-06 Insmed Inc Formulaciones de vancomicina estabilizadas.
JP6399663B2 (ja) 2013-03-14 2018-10-03 インターセクト エント， インコーポレイテッド 副鼻腔状態を処置するためのシステム、デバイスおよび方法
JP2016520086A (ja) * 2013-05-17 2016-07-11 ユタ ステート ユニバーシティ アミノグリコシドおよびアゾール組成物および方法
CN104208701A (zh) * 2013-05-29 2014-12-17 天津金耀集团有限公司 含有抗真菌药物的复方吸入制剂
FR3009622B1 (fr) * 2013-08-09 2015-08-07 Novacyt Procede et dispositif de lavage d'un dispositif de pipetage-distribution
WO2015031393A1 (fr) 2013-08-27 2015-03-05 Otonomy, Inc. Méthodes pour le traitement de troubles otiques chez les enfants
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
SMT202000516T1 (it) 2014-05-15 2020-11-10 Insmed Inc Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari
AU2015348043B2 (en) * 2014-11-21 2019-08-22 F2G Limited Antifungal agents
JP2018504209A (ja) 2015-01-22 2018-02-15 インターセクト エント， インコーポレイテッド 薬物コーティングバルーン
US20180071281A1 (en) * 2016-08-19 2018-03-15 Gerbe Labs Inc. Treating chronic rhinosinusitis
WO2018053173A1 (fr) 2016-09-16 2018-03-22 Otonomy, Inc. Formulations de gel otique pour le traitement de l'otite externe
WO2018226339A1 (fr) 2017-06-06 2018-12-13 Glaxosmithkline Llc Compositions biopharmaceutiques et procédés pour patients pédiatriques
US11712436B2 (en) * 2017-12-20 2023-08-01 Cornell University Theranostic test for antifungal treatment of inflammatory diseases
CN112040950A (zh) * 2018-03-19 2020-12-04 上海偕怡医药科技有限公司 治疗特发性肺纤维化的方法和组合物
WO2019191627A1 (fr) 2018-03-30 2019-10-03 Insmed Incorporated Procédés pour la fabrication continue de produits médicamenteux liposomaux
WO2019213398A1 (fr) 2018-05-02 2019-11-07 Insmed Incorporated Procédés de fabrication de formulations de médicament liposomal
CN111249219B (zh) * 2018-11-30 2023-08-11 中南大学湘雅三医院 治疗耳道真菌的滴耳液及其制备方法
CA3130138A1 (fr) * 2019-02-27 2020-09-03 Oticara, Inc. Methode de traitement d'une infection et/ou d'une inflammation nasale, nasosinusienne et rhinopharyngienne
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
US12403291B2 (en) 2019-08-30 2025-09-02 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform
WO2021194893A1 (fr) 2020-03-24 2021-09-30 Cyrano Therapeutics, Inc. Traitement d'un dysfonctionnement chimiosensoriel résultant d'une infection à coronavirus

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
DE2350315C2 (de) * 1973-10-06 1984-01-12 Johnson & Johnson GmbH, 4000 Düsseldorf Pharmazeutische und kosmetische Präparate zur äußerlichen Anwendung
US4209447A (en) 1975-01-27 1980-06-24 Janssen Pharmaceutica N.V. Imidazole derivatives and intermediates in their preparation
US3991750A (en) 1975-04-28 1976-11-16 Syntex Corporation Dromostanolone propionate implant pellet useful for producing weight gains in animals and suppressing estrus in female animals
US4402957A (en) 1979-04-04 1983-09-06 Janssen Pharmaceutica N.V. Heterocyclic derivatives of [4-(piperazin-1-ylphenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4334538A (en) 1979-12-12 1982-06-15 Juhn Steven K Aspirator for collecting liquid samples
US4432991A (en) 1981-07-13 1984-02-21 American Cyanamid Company Therapeutically active 3-amino-1-phenyl(and substituted phenyl)-2-pyrazolines
US4883785A (en) 1984-07-27 1989-11-28 Chow Wing Sun Complex of anti-fungal agent and cyclodextrin and method
US4916134A (en) 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
US5487739A (en) 1987-11-17 1996-01-30 Brown University Research Foundation Implantable therapy systems and methods
US5075309A (en) 1989-06-09 1991-12-24 Janssen Pharmaceutica N.V. Antifungal 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]triazolones and imidazolones
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5310545A (en) * 1991-04-11 1994-05-10 Drore Eisen Method of treatment using mouthwashes containing steroids and antifungal agents and compositions of matter
US5248504A (en) 1992-03-02 1993-09-28 Friedman William H Method of treatment for nasal and sinus dysfunction
EP1132080A3 (fr) 1992-09-10 2001-10-17 Children's Medical Center Corporation Matrices en polymère biodégradables pour la libération prolongée d'agents anesthésiants locaux
CA2106034A1 (fr) 1992-09-24 1994-03-25 Ralph J. Russo La 21-norrapamycine
CA2153681C (fr) 1993-01-21 2004-05-25 Marc Karel Jozef Francois Compositions topiques a base de cetoconazole
RU2128053C1 (ru) 1993-03-19 1999-03-27 Налепо Лидия Филимоновна Средство для лечения бронхиальной астмы (варианты)
TW349870B (en) 1993-09-30 1999-01-11 Janssen Pharmaceutica Nv An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
US5582167A (en) 1994-03-02 1996-12-10 Thomas Jefferson University Methods and apparatus for reducing tracheal infection using subglottic irrigation, drainage and servoregulation of endotracheal tube cuff pressure
US5952314A (en) * 1994-04-01 1999-09-14 Demichele; Stephen Joseph Nutritional product for a person having ulcerative colitis
CA2194049A1 (fr) * 1994-06-28 1996-01-11 Georgi Stankov Nouvelles utilisations cliniques de polyenes-macrolides
US5599795A (en) * 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
US5658881A (en) 1994-10-14 1997-08-19 Twk, Inc. Method for topical inhibition of the metabolic activity of cytochrome P450
US5679648A (en) * 1994-11-30 1997-10-21 The University Hospital Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides
US5614206A (en) 1995-03-07 1997-03-25 Wright Medical Technology, Inc. Controlled dissolution pellet containing calcium sulfate
JP3434396B2 (ja) * 1995-06-30 2003-08-04 株式会社日立ユニシアオートモティブ 鼻腔用投薬器
GB9514878D0 (en) 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
DE19541815B4 (de) * 1995-11-09 2008-04-10 Bannert, Christian, Dr. Verwendung einer Lösung von Polyethylenglykol in Wasser als wässrige Spüllösung zur Prävention oder Behandlung von zähem Schleim, der in Verbindung mit Strahlen- oder/und Chemotherapie-induzierten Erkrankungen der Schleimhäute auftritt
US5756127A (en) 1996-10-29 1998-05-26 Wright Medical Technology, Inc. Implantable bioresorbable string of calcium sulfate beads
RU2139707C1 (ru) 1996-12-24 1999-10-20 ОАО Нижегородский химико-фармацевтический завод Суппозитории, обладающие противогрибковым действием (варианты)
US20020052390A1 (en) * 1997-10-22 2002-05-02 Jens Ponikau Methods and materials for treating and preventing inflammation of mucosal tissue
US5897872A (en) 1997-11-12 1999-04-27 Picciano; Dante J. Iodine-containing nasal moisturizing saline solution
CA2318264A1 (fr) 1998-01-30 1999-08-05 Wilk Patent Development Corporation Revascularisation et pontage aorto-coronarien transmyocardique

Also Published As

Publication number Publication date
JP2007008951A (ja) 2007-01-18
US6291500B2 (en) 2001-09-18
AP2000001805A0 (en) 2000-06-30
HK1029935A1 (en) 2001-04-20
BG104371A (en) 2000-12-29
PL340606A1 (en) 2001-02-12
AU1195999A (en) 1999-05-10
IL135774A0 (en) 2001-05-20
KR20060002015A (ko) 2006-01-06
CA2308201A1 (fr) 1999-04-29
CN1143679C (zh) 2004-03-31
US20090253645A1 (en) 2009-10-08
WO1999020261A2 (fr) 1999-04-29
NO20002069L (no) 2000-06-21
JP2006096770A (ja) 2006-04-13
NO20002069D0 (no) 2000-04-19
EP1024814A2 (fr) 2000-08-09
NO325714B1 (no) 2008-07-07
CN1282251A (zh) 2001-01-31
KR100883149B1 (ko) 2009-02-10
US20030091510A1 (en) 2003-05-15
EP1024814B1 (fr) 2007-08-29
US20020052390A1 (en) 2002-05-02
KR20010031363A (ko) 2001-04-16
SK5732000A3 (en) 2000-10-09
US20010006944A1 (en) 2001-07-05
US6207703B1 (en) 2001-03-27
EA200000439A1 (ru) 2000-12-25
ES2292210T3 (es) 2008-03-01
KR20060066753A (ko) 2006-06-16
TR200001117T2 (tr) 2000-09-21
PT1024814E (pt) 2007-11-29
CA2308201C (fr) 2010-09-28
ATE371457T1 (de) 2007-09-15
DK1024814T3 (da) 2008-01-02
EP1857113A2 (fr) 2007-11-21
WO1999020261A3 (fr) 2000-02-17
BR9814615A (pt) 2001-10-16
IL135774A (en) 2006-08-20
EE200000253A (et) 2001-06-15
US20030153516A1 (en) 2003-08-14
DE69838338D1 (de) 2007-10-11
US20010002400A1 (en) 2001-05-31
IS5463A (is) 2000-04-19
EP1857113A3 (fr) 2007-12-19
JP2001520188A (ja) 2001-10-30
KR20070069220A (ko) 2007-07-02
ID26104A (id) 2000-11-23
US20010031779A1 (en) 2001-10-18
US20050124561A1 (en) 2005-06-09
HUP0004170A3 (en) 2001-12-28
US6555566B2 (en) 2003-04-29
HUP0004170A2 (hu) 2001-05-28
DE69838338T2 (de) 2008-05-21

Similar Documents

Publication Publication Date Title
US6291500B2 (en) Methods and materials for treating and preventing inflammation of mucosal tissue
WO2021151100A1 (fr) Procédés, compositions et vaccins pour le traitement d&#39;une infection virale
TWI236905B (en) Pharmaceutical composition for treating and preventing inflammation of mucosal tissue
AU2005202469C1 (en) Methods and materials for treating and preventing inflammation of mucosal tissue
EP2079306A2 (fr) Formulation d&#39;amphotéricine b n&#39;irritant pas les muqueuses, et procédés pour traiter une mucosite non-invasive induite par un champignon
HK1112405A (en) Use of antifungal agents for the topical treatment of asthma
HK1029935B (en) Use of antifungal agents for the topical treatment of fungus-induced mucositis
AU2008229980A1 (en) Methods and materials for treating and preventing inflammation of mucosal tissue
MXPA00003909A (en) Methods and materials for treating and preventing inflammation ofmucosal tissue
CZ20001476A3 (cs) Materiály pro léčbu a prevenci zánětu mukózní tkáně
WO2009102814A2 (fr) Formulation d&#39;amphotéricine b liquide n&#39;irritant pas les muqueuses, et procédé pour traiter une mucosite non invasive induite par champignon